Study of visual and anatomical outcomes of second year aflibercept in good visual acuity baseline of wet age-related macular degeneration

Study of visual and anatomical outcomes of second year aflibercept in good visual acuity baseline of wet age-related macular degeneration - Study of second year aflibercept in patients with wAMD

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000016598

Enrollment

Registered

2015-02-22

Start date

2015-02-22

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Age-related macular degeneration

Interventions

Eylea (aflibercept)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) baseline BCVA in the study eye over 0.5 (Decimal VA) 2) AMD with Subfoveal fluid on fluorescent angiography, indocyanine green angiography and/or optical coherence tomography 3) Willingness to provide written informed consent 4) outpatient 5) second year aflibercept treatment

Exclusion criteria

Exclusion criteria: 1) Greatest Linear Dimension (GLD) of the total lesion area <12 Macular Photocoagulation Study Disc Areas 2) Presence of subretinal hemorrhage, scar or macular fibrosis (>50% lesion area) 3) Prior treatment with anti-VEGF drug, photodynamic therapy 4) Prior treatment with dexamethasone (<6 months) or triamcinolone (<30 days), intraocular surgery (<3 months) 5) Active intraocular inflammation 6) Hypersensitivity or allergy to fluorescein or indocyanine green, clinically significant drug allergy or known hypersensitivity to therapeutic or diagnostic protein products 7) Patient who the doctor in charge judges are ineligible for the study

Design outcomes

Primary

Measure	Time frame
Change of best-collected visual acuity and proportion of improved, maintained and deteriorated visual acuity at month 24 from 12 after initial injection of aflibercept	—

Secondary

Measure	Time frame
Change of (best-collected visual acuity) BCVA, central macular thickness, subretinal fluid and polyps regression	—

Countries

Japan

Contacts

Public ContactHidenori Takahashi

Jichi Medical University Department of Ophthalmology

takahah-tky@umin.ac.jp0285-58-7382

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026